Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting

Phase 1

Trametinib & EverolimusTrametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Sponsor:

UCLA

Code:

NCT04485559

Conditions

Recurrent World Health Organization (WHO) Grade II Glioma

Low-grade Glioma

High Grade Glioma

Eligibility Criteria

Sex: All

Age: 1 - 25

Healthy Volunteers: Not accepted

Interventions

Everolimus

Trametinib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-02. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2025-06-06.